Compare TPC & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPC | FOLD |
|---|---|---|
| Founded | 1894 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.5B |
| IPO Year | 2003 | 2006 |
| Metric | TPC | FOLD |
|---|---|---|
| Price | $85.49 | $14.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $86.00 | $27.25 |
| AVG Volume (30 Days) | 380.9K | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | ★ 148.24 | 50.00 |
| EPS | ★ 1.51 | N/A |
| Revenue | ★ $5,543,039,000.00 | N/A |
| Revenue This Year | $15.37 | $20.50 |
| Revenue Next Year | $9.99 | $18.59 |
| P/E Ratio | $57.55 | ★ N/A |
| Revenue Growth | ★ 28.11 | N/A |
| 52 Week Low | $21.40 | $5.66 |
| 52 Week High | $89.51 | $14.50 |
| Indicator | TPC | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 60.68 | 74.18 |
| Support Level | $66.91 | $14.21 |
| Resistance Level | $89.46 | N/A |
| Average True Range (ATR) | 2.58 | 0.02 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 65.67 | 100.00 |
Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically it derives key revenue from the United States.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.